{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to LRRK2 kinase activity alterations leading to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The assays used (binding and enzymatic) are appropriate for evaluating kinase activity alterations, which are central to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of replicates, indicating reliability of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Measured affinities (EC 50 values) for I2020T and G2019S for all compounds were within 1.6-fold of wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Wild-type LRRK2 was used as a control, providing a baseline for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "I2020T is resistant to inhibition by ATP-competitive inhibitors at cellular levels of ATP.",
          "judgment": "Yes",
          "reasoning": "The data supports a pathogenic effect of the I2020T mutation through altered kinase activity and inhibitor resistance.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The ATP K m for I2020T was found to be 7.5 Â± 0.4 lM, which is 7-fold lower than that for wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The study provides quantitative data on ATP affinity changes, supporting the pathogenic nature of the mutation.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The I2020T mutation in LRRK2 demonstrates altered kinase activity and ATP affinity, supporting its pathogenic role in PD with moderate strength evidence."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to LRRK2 kinase activity alterations leading to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The assays used (binding and enzymatic) are appropriate for evaluating kinase activity alterations, which are central to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of replicates, indicating reliability of the assay results.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Measured affinities (EC 50 values) for I2020T and G2019S for all compounds were within 1.6-fold of wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Wild-type LRRK2 was used as a control, providing a baseline for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "G2019S is slightly more sensitive than wild-type LRRK2 to ATP-competitive inhibitors at cellular levels of ATP.",
          "judgment": "Yes",
          "reasoning": "The data supports a pathogenic effect of the G2019S mutation through altered kinase activity and inhibitor sensitivity.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The ATP K m,app value for G2019S (169 lM) to be approximately 3-fold higher than wild-type LRRK2 (51 lM), whereas the specific activity for G2019S was approximately 3-fold higher.",
          "judgment": "Yes",
          "reasoning": "The study provides quantitative data on ATP affinity changes, supporting the pathogenic nature of the mutation.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2019S mutation in LRRK2 demonstrates altered kinase activity and ATP affinity, supporting its pathogenic role in PD with moderate strength evidence."
    }
  ]
}